HENGRUI PHARMA (01276.HK): Six Drugs Cleared for Clinical Trials, Including Two ADCs

NewTimeSpace News: On 13 November 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 1276) published an overseas regulatory announcement reproducing its disclosure on the Shanghai Stock Exchange website. The Company and its subsidiaries received drug clinical trial approval notices from China's National Medical Products Administration for SHR-4610 injection, SHR-9839 for injection (sc), SHR-A2102 for injection, SHR-4849 injection, SHR-7787 injection and HRS-4508 tablets, which will enter clinical trials shortly.

The applications were accepted on 5 August 2026 and were approved after review. SHR-4610 injection is an in-house innovative anti-tumour drug for advanced solid tumours, with cumulative R&D spending of about RMB16.8 million; SHR-9839 is a humanised antibody drug, and its subcutaneous formulation is intended for advanced solid tumours, with one same-target drug already approved globally and cumulative R&D spending of about RMB127.8 million.

SHR-A2102 for injection is a Nectin-4-targeting antibody-drug conjugate; one comparable product, enfortumab vedotin (Padcev), is approved globally, with 2025 global sales of about US$2.473 billion, and the project's cumulative R&D spending is about RMB455.1 million. SHR-4849 injection is a DLL3-targeting ADC with no approved counterpart in China or abroad and cumulative R&D spending of about RMB100.9 million. SHR-7787 injection is a Class 1 therapeutic biologic that activates T cells, with spending of about RMB72.6 million, while HRS-4508 tablets are a selective tyrosine kinase inhibitor comparable to zongertinib and tucatinib, with spending of about RMB110.1 million.

The Company cautioned that the drugs must complete clinical trials and obtain NMPA approval before they can be manufactured and sold, and that development is lengthy and subject to uncertainty.